Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Weiser

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Current Drug Safety|April 18, 2022
Lack of Evidence for Blood Pressure Effects of Caffeine Added to IbuprofenAnette Lampert, Robert Lange, Thomas Weiser
Springerplus|July 5, 2016
Results from a pharmacy-based patient survey on the use of a fixed combination analgesic containing acetylsalicylic acid, paracetamol and caffeine by self-diagnosing and self-treating patientsCharly Gaul, Heidemarie Gräter, Thomas Weiser
Lakartidningen|June 20, 2018
Alex Haynes, Thomas Weiser, Pelle Gustafson
MMWR. Morbidity and Mortality Weekly Report|December 21, 2018
Drug, Opioid-Involved, and Heroin-Involved Overdose Deaths Among American Indians and Alaska Natives - Washington, 1999-2015Sujata Joshi, Thomas Weiser, Victoria Warren-Mears
Pain and Therapy|January 9, 2020
A Randomized, Double-Blind, Placebo-Controlled Trial of Ibuprofen Lysinate in Comparison to Ibuprofen Acid for Acute Postoperative Dental PainJán Kyselovič, Eva Koscova, Anette Lampert, et al.
Clinical Pharmacology in Drug Development|March 22, 2019
Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed-Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions-Data From 2 Single-Center, Single-Dose, Randomized Crossover Studies in Healthy VolunteersThomas Weiser, Cornelia Schepers, Tobias Mück, et al.
Frontiers in Neurology|November 9, 2023
Correlation of effectiveness and tolerability assessments from a pharmacy-based observational study investigating the fixed-dose combination of 400 mg ibuprofen plus 100 mg caffeine for the treatment of acute headacheCharly Gaul, Stefanie Förderreuther, Walter Lehmacher, et al.
Neuropharmacology|September 27, 2005
Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory painWolfram Gaida, Klaus Klinder, Kirsten Arndt, et al.
European Journal of Neurology|September 14, 2021
Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trialsHans Christoph Diener, Charly Gaul, Walter Lehmacher, et al.
Archives of Pediatrics & Adolescent Medicine|September 5, 2007
Communitywide outbreak of cryptosporidiosis in rural Missouri associated with attendance at child care centersGeorge Turabelidze, Mei Lin, Thomas Weiser, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Current Drug Safety|April 18, 2022
Lack of Evidence for Blood Pressure Effects of Caffeine Added to IbuprofenAnette Lampert, Robert Lange, Thomas Weiser
Springerplus|July 5, 2016
Results from a pharmacy-based patient survey on the use of a fixed combination analgesic containing acetylsalicylic acid, paracetamol and caffeine by self-diagnosing and self-treating patientsCharly Gaul, Heidemarie Gräter, Thomas Weiser
Lakartidningen|June 20, 2018
Alex Haynes, Thomas Weiser, Pelle Gustafson
MMWR. Morbidity and Mortality Weekly Report|December 21, 2018
Drug, Opioid-Involved, and Heroin-Involved Overdose Deaths Among American Indians and Alaska Natives - Washington, 1999-2015Sujata Joshi, Thomas Weiser, Victoria Warren-Mears
Pain and Therapy|January 9, 2020
A Randomized, Double-Blind, Placebo-Controlled Trial of Ibuprofen Lysinate in Comparison to Ibuprofen Acid for Acute Postoperative Dental PainJán Kyselovič, Eva Koscova, Anette Lampert, et al.
Clinical Pharmacology in Drug Development|March 22, 2019
Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed-Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions-Data From 2 Single-Center, Single-Dose, Randomized Crossover Studies in Healthy VolunteersThomas Weiser, Cornelia Schepers, Tobias Mück, et al.
Frontiers in Neurology|November 9, 2023
Correlation of effectiveness and tolerability assessments from a pharmacy-based observational study investigating the fixed-dose combination of 400 mg ibuprofen plus 100 mg caffeine for the treatment of acute headacheCharly Gaul, Stefanie Förderreuther, Walter Lehmacher, et al.
Neuropharmacology|September 27, 2005
Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory painWolfram Gaida, Klaus Klinder, Kirsten Arndt, et al.
European Journal of Neurology|September 14, 2021
Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trialsHans Christoph Diener, Charly Gaul, Walter Lehmacher, et al.
Archives of Pediatrics & Adolescent Medicine|September 5, 2007
Communitywide outbreak of cryptosporidiosis in rural Missouri associated with attendance at child care centersGeorge Turabelidze, Mei Lin, Thomas Weiser, et al.
Pageof 7